Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for modafinil (compound)


PubChem
Name: modafinil
PubChem Compound ID: 11173366
Molecular formula: C15H15NO2S
Molecular weight: 273.351 g/mol
DrugBank
Identification
Name: modafinil
Name (isomeric): DB00745
Drug Type: small molecule
Synonyms:
Modafinil [USAN:INN]; Modafinilo [Spanish]; Moderateafinil; Modafinilum [Latin]
Brand: Sparlon, Provigil, Modiodal
Category: Anorexigenic Agents, Stimulants, Central Nervous System Stimulants, Neuroprotective Agents, Central Nervous System Agents
CAS number: 68693-11-8
Pharmacology
Indication: To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
Pharmacology:
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with ps...
show more »
Mechanism of Action:
The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other s...
show more »
Absorption: Rapid following oral administration.
Protein binding: 60%
Biotransformation: Hepatic
Route of elimination: The major route of elimination is metabolism (~90%), primarily by the liver, with subsequent renal elimination of the metabolites.
Half Life: 23-215 hours
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Take without regard to meals.
Drug interaction:
CyclosporineModafinil decreases the effect of cyclosporine
Ethinyl EstradiolModafinil may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on during concomitant therapy with modafinil.
TrimipramineThe strong CYP2C19 inhibitor, Modafinil, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Modafinil is initiated, discontinued or dose changed.
CarisoprodolStrong CYP2C19 inhibitors such as modafinil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
TriazolamModafinil decreases the effect of triazolam
show more »

Targets


Enzymes